Insider trading

Period: 120 months Stock: DGX + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

182 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

182 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

182 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

182 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
182 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
182 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

182 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
14 Oct 2020
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$4.24M 35,591 at 119.00
47.0%
2 Sep 2020
Doherty Catherine T. SVP, Group Exec. Clin. Fran.
Sold, plan not stated 2×
$6.46M 58,392 at 110.60
46.0%
8 Jun 2020
GUINAN MARK Executive Vice President & CFO
Sold, plan not stated 3×
$8.51M 72,596 at 117.23
49.7%
8 Jun 2020
RING TIMOTHY M Director
Sold, plan not stated
$1.37M 11,730 at 116.60
36.4%
27 Apr 2020
RUSCKOWSKI STEPHEN H Chairman, CEO and President
Sold, plan not stated
$1.31M 11,717 at 112.01
4.7%
27 Apr 2020
EGLINTON MANNER CARRIE SVP, Advanced Diagnostics
Sold, plan not stated 2×
$555.08K 5,000 at 111.02
18.3%
16 Mar 2020
Davis J. E. EVP, General Diagnostics
Sold, plan not stated 5×
$308.25K 3,513 at 87.75
8.4%
11 Mar 2020
Doherty Catherine T. SVP, Group Exec. Clin. Fran.
Sold, plan not stated
$260.73K 2,501 at 104.25
3.5%
11 Mar 2020
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$226.74K 2,175 at 104.25
5.1%
10 Mar 2020
RUSCKOWSKI STEPHEN H Chairman, CEO and President
Sold, plan not stated
$11.22K 100 at 112.19
0.0%
6 Mar 2020
RUSCKOWSKI STEPHEN H Chairman, CEO and President
Sold, plan not stated 5×
$25.93M 230,178 at 112.67
50.4%
Sold half or more
27 Feb 2020
Davis J. E. EVP, General Diagnostics
Sold, plan not stated
$119.92K 1,100 at 109.02
2.8%
27 Feb 2020
Doherty Catherine T. SVP, Group Exec. Clin. Fran.
Sold, plan not stated
$86.02K 789 at 109.02
1.1%
27 Feb 2020
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$75.22K 690 at 109.02
1.7%
26 Feb 2020
Davis J. E. EVP, General Diagnostics
Sold, plan not stated
$56.66K 510 at 111.09
1.2%
26 Feb 2020
Doherty Catherine T. SVP, Group Exec. Clin. Fran.
Sold, plan not stated
$40.88K 368 at 111.09
0.5%
26 Feb 2020
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$35.66K 321 at 111.09
0.8%
25 Feb 2020
Davis J. E. EVP, General Diagnostics
Sold, plan not stated
$67.41K 598 at 112.73
1.4%
25 Feb 2020
Doherty Catherine T. SVP, Group Exec. Clin. Fran.
Sold, plan not stated
$45.66K 405 at 112.73
0.6%
2 Jan 2020
Davis J. E. EVP, General Diagnostics
Sold, plan not stated 4×
$15.15M 143,537 at 105.57
79.7%
Sold half or more
27 Nov 2019
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated 3×
$4.79M 44,556 at 107.43
53.0%
Sold half or more
26 Nov 2019
WILENSKY GAIL R Director
Sold, plan not stated
$857.35K 8,000 at 107.17
34.9%
17 Sep 2019
Deppe Michael J VP, Corp. Controller & CAO
Sold, plan not stated
$530.00K 5,000 at 106.00
17.4%
13 Jun 2019
RUSCKOWSKI STEPHEN H Chairman, President and CEO
Sold, plan not stated
$24.46M 244,565 at 100.00
53.4%
Sold half or more
13 Jun 2019
GUINAN MARK Executive Vice President & CFO
Sold, plan not stated
$7.30M 73,005 at 100.00
52.5%
Sold half or more
24 Apr 2019
Davis J. E. EVP, General Diagnostics
Sold, plan not stated
$4.52M 47,574 at 95.00
56.6%
Sold half or more
8 Apr 2019
Davis J. E. EVP, General Diagnostics
Sold, plan not stated 2×
$722.33K 8,000 at 90.29
18.0%
4 Apr 2019
Doherty Catherine T. SVP, Group Exec. Clin. Fran.
Sold, plan not stated 2×
$6.01M 66,382 at 90.59
49.6%
4 Mar 2019
Cunningham Everett SVP, Commercial
Sold, plan not stated
$337.86K 3,892 at 86.81
9.2%
4 Mar 2019
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$292.81K 3,373 at 86.81
7.9%
27 Feb 2019
Cunningham Everett SVP, Commercial
Sold, plan not stated
$98.97K 1,144 at 86.51
2.9%
27 Feb 2019
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$90.66K 1,048 at 86.51
2.6%
26 Feb 2019
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$31.69K 364 at 87.06
0.9%
26 Feb 2019
Cunningham Everett SVP, Commercial
Sold, plan not stated
$30.65K 352 at 87.06
0.9%
25 Feb 2019
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$29.65K 336 at 88.23
0.8%
25 Feb 2019
Cunningham Everett SVP, Commercial
Sold, plan not stated
$28.76K 326 at 88.23
0.8%
22 Feb 2019
WILENSKY GAIL R Director
Sold, plan not stated
$702.22K 8,000 at 87.78
23.1%
10 Jul 2018
Cunningham Everett SVP, Commercial
Sold, plan not stated
$4.52M 40,328 at 112.00
51.3%
Sold half or more
10 Jul 2018
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$3.48M 30,780 at 113.07
43.6%
2 Jul 2018
Cunningham Everett SVP, Commercial
Sold, plan not stated 6×
$7.47M 68,069 at 109.67
64.0%
Sold half or more
29 May 2018
LEIDEN JEFFREY M Director
Sold, plan not stated
$173.62K 1,644 at 105.61
21.5%
25 May 2018
RUSCKOWSKI STEPHEN H Chairman, President and CEO
Sold, plan not stated
$18.03M 168,490 at 107.00
46.9%
25 May 2018
GUINAN MARK Executive Vice President & CFO
Sold, plan not stated 2×
$6.50M 61,533 at 105.71
51.4%
Sold half or more
8 Mar 2018
Cohen Jon R SVP & Group Exec. Diag. Sol.
Sold, plan not stated 7×
$8.72M 83,669 at 104.20
72.5%
Sold half or more
5 Mar 2018
Doherty Catherine T. SVP, Group Exec. Clin. Fran.
Sold, plan not stated
$561.16K 5,556 at 101.00
7.6%
5 Mar 2018
Davis J. E. EVP, General Diagnostics
Sold, plan not stated
$517.32K 5,122 at 101.00
12.1%
5 Mar 2018
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$416.93K 4,128 at 101.00
9.4%
28 Feb 2018
Davis J. E. EVP, General Diagnostics
Sold, plan not stated
$68.03K 648 at 104.99
1.7%
28 Feb 2018
Doherty Catherine T. SVP, Group Exec. Clin. Fran.
Sold, plan not stated
$60.05K 572 at 104.99
0.8%
28 Feb 2018
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$52.08K 496 at 104.99
1.2%
Showing 101–150 of 182. ← Newer Page 3 of 4 Older →